HLA-A allele-lacking leukocytes (HLA-LLs) were detected in 25.4% of newly diagnosed patients with aplastic anemia.
•
The presence of HLA-LLs at diagnosis was strongly related to good clinical outcomes.
•
T-cell attacks against hematopoietic progenitor cells can trigger bone marrow failure.
To gain insight into the origin and clinical significance of leukocytes that lack human leukocyte antigen A (HLA-A) allele expression caused by a copy-number-neutral loss of heterozygosity in the short arm of chromosome 6 in patients with acquired aplastic anemia (AA), we used a high-sensitivity flow cytometry assay to investigate the presence of HLA-A allele-lacking leukocytes (HLA-LLs) in 144 AA patients. HLA-LLs, accounting for 0.2–99.8% of each leukocyte population, were detected in 18 of 71 (25.4%) newly diagnosed patients and in 25 of 73 (34.2%) previously treated patients. The lineage combination patterns of the HLA-LLs in the 43 HLA-LL+ patients were granulocytes (Gs), monocytes (Ms), B cells (Bs), and T cells (Ts; GMBT) in 13 cases, GMB in 16 cases, GM in 11 cases, and B alone in three cases. The response rate to antithymocyte globulin plus cyclosporine therapy (100%) and the 2-year, failure-free survival rate (100%) in 8 newly diagnosed HLA-LL+ patients were significantly higher than in 23 HLA-LL− patients (52.2% for both). These data suggest that HLA-LLs are a useful marker of the presence of immune pathophysiology in AA and that T-cell attacks against hematopoietic progenitor cells, rather than against hematopoietic stem cells, can trigger bone marrow failure in AA patients.
Cited by (0)
HM and TK contributed equally to this work. SN developed the study concept and HM, TK, and SN designed the experiments. HM, TK, YZ, KM, KH, KI, HY, TS, AS-O, HI, and SO performed the experiments and analyzed the data. KK performed high-resolution HLA typing. HM, TK, and SN wrote the paper. All authors approved the final version of this paper.